Telix Pharmaceuticals (ASX: TLX) reported a strong revenue growth of 11% to $320 million for the quarter ending March 2026, reinforcing full-year revenue guidance of $1.3 billion to $1.7 billion. This growth is largely driven by their Precision Medicine segment, particularly in the U.S. market, where their dual-product strategy in PSMA imaging is gaining traction. Key milestones include successful early results in a Phase 3 trial for their lead prostate cancer therapy and ongoing advancements in trials for other cancers like kidney and glioblastoma. Additionally, the company is progressing with regulatory submissions for a brain cancer imaging agent in both the U.S. and Europe. CEO Dr. Christian Behrenbruch highlighted the company’s solid foundations for continued growth through 2026, backed by disciplined sales execution and high-quality service.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://biotechdispatch.com.au/news/telix-reports-strong-revenue-growth-and-therapeutics-pipeline-advancement
